Motorola a Match for Incyte Content

Incyte Genomics licensed its portfolio of proprietary gene sequences to Motorola's BioChip Systems division, which will use the information to make bioarrays for gene expression, SNP scoring, genotyping, and protein expression. In addition, Motorola software will enable users to click through to Incyte's Web site for the purchase of additional gene sequence information and reagents, a much-needed boost to Incyte's attempts to direct researchers to its Web-based genomics database.

In keeping with its open platform strategy, Incyte Genomics Inc. licensed its portfolio of proprietary gene sequences, including the LifeSeq Gold and ZooSeq databases, to Motorola Inc. 's BioChip Systems unit, which will use the information to make bioarrays used for gene expression, SNP scoring, genotyping, and protein expression. It becomes the first biochip manufacturer to take a license from Incyte, which will get royalties on array sales.

Motorola BioChip Systems, which only began beta testing its products earlier this year, is positioning itself to become a low-cost,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business Strategy

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By 

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

AI In Drug Discovery: The Patent Implications

 
• By 

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.

Is Advanced AI Revolutionizing Sales Enablement In Pharma?

 
• By 

Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By 

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By 

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.